argenx NV ADR (ARGX)vsMoonLake Immunotherapeutics (MLTX)
ARGX
argenx NV ADR
$888.65
+5.82%
HEALTHCARE · Cap: $56.45B
MLTX
MoonLake Immunotherapeutics
$19.90
+2.24%
HEALTHCARE · Cap: $1.41B
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
MLTX
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.1%
Fair Value
$2204.33
Current Price
$888.65
$1315.68 discount
Intrinsic value data unavailable for MLTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
No standout strengths identified
Areas to Watch
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 187.9x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : MLTX
MLTX has a balanced fundamental profile.
Bear Case : ARGX
The primary concerns for ARGX are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 40.2x leaves little room for execution misses.
Bear Case : MLTX
The primary concerns for MLTX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while MLTX is a value play — different risk/reward profiles.
MLTX carries more volatility with a beta of 1.04 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 23/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
MoonLake Immunotherapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
MoonLake Immunotherapeutics is a pioneering biotechnology company focused on the development of advanced therapies for chronic inflammatory diseases, utilizing its proprietary drug delivery technology. The firm is currently progressing its lead candidate, a novel interleukin-17 inhibitor, through multiple phases of clinical trials, which could significantly reshape treatment approaches and enhance patient outcomes. With a strong research pipeline and strategic partnerships, MoonLake Immunotherapeutics is well-positioned to address substantial unmet medical needs in the immunotherapy landscape, offering considerable investment potential.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?